Immunovant, Inc.
IMVT
$15.80
-$0.06-0.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.98% | 7.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.42% | -1.24% | |||
| Operating Income | 0.42% | 1.24% | |||
| Income Before Tax | 4.60% | -1.77% | |||
| Income Tax Expenses | 283.55% | 94.87% | |||
| Earnings from Continuing Operations | 4.21% | -1.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.21% | -1.84% | |||
| EBIT | 0.42% | 1.24% | |||
| EBITDA | 0.43% | 1.25% | |||
| EPS Basic | 15.59% | -1.52% | |||
| Normalized Basic EPS | 15.95% | -1.46% | |||
| EPS Diluted | 15.59% | -1.52% | |||
| Normalized Diluted EPS | 15.95% | -1.46% | |||
| Average Basic Shares Outstanding | 13.48% | 0.31% | |||
| Average Diluted Shares Outstanding | 13.48% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||